Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
Africa’s Biggest Drugmaker Can Help Ease Obesity Medicine Supply Crunch
11 Best Low Price Pharma Stocks To Invest In
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Bill Miller’s Latest 13 Stock Picks
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
Do cash-gushing stocks outperform the S&P 500? Here’s what history has to say.
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
UK's Theramex sees no impact to HRT products supply after CMA probe
Competition watchdog says HRT drug deal could raise prices
UPDATE 1-UK watchdog says Theramex-Viatris deal raises competition concerns
UK watchdog says Theramex-Viatris deal raises competition concerns
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.